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ABSTRACT:
The  peroxisome  proliferator-activated  receptorγ  (PPARγ)  is  a  key  regulator  of 
metabolism,  proliferation,  inflammation  and  differentiation,  and  upregulates 
tumor suppressor genes, such as PTEN, BRCA1 and PPARγ itself. Examination of 
mammary carcinogenesis in transgenic mice expressing the dominant-negative 
Pax8PPARγ fusion protein revealed that tumors were estrogen receptorα (ER)-
positive and sensitive to the ER antagonist, fulvestrant. Here we evaluated whether 
administration of an irreversible PPARγ inhibitor in vivo could similarly induce 
ER  expression  in  otherwise  ER-negative  mammary  tumors  following  induction 
of carcinogenesis, and sensitize them to the antitumor effects of fulvestrant. In 
addition, we wished to determine whether the effect of GW9662 was associated 
with  a  PPAR-selective  gene  expression  profile.  Mammary  carcinogenesis  was 
induced  in  wild-type  FVB  mice  by  treatment  with  medroxyprogesterone  and 
dimethylbenz(a)anthracene (DMBA) that were subsequently maintained on a diet 
supplemented with 0.1% GW9662, and tumorigenesis and gene expression profiling 
of the resulting tumors were determined. Administration of GW9962 resulted in 
ER+ tumors that were highly sensitive to fulvestrant. Tumors from GW9662-treated 
animals exhibited reduced expression of a metabolic gene profile indicative of 
PPARγ inhibition, including PPARγ itself. Additionally, GW9662 upregulated the 
expression of several genes associated with the transcription, processing, splicing 
and translation of RNA. This study is the first to show that an irreversible PPARγ 
inhibitor can mimic a dominant-negative PPARγ transgene to elicit the development 
of  ER-responsive  tumors.  These  findings  suggest  that  it  may  be  possible  to 
pharmacologically influence the responsiveness of tumors to anti-estrogen therapy. 
INTRODUCTION
The peroxisome proliferator-activated receptor 
(PPAR) nuclear receptor subfamily regulates a number 
of metabolic processes, including fatty acid β-oxidation, 
glucose utilization, cholesterol transport, energy balance 
and adipocyte differentiation [1-4]. PPARs also play 
important roles in modulating inflammation, proliferation, 
angiogenesis and neoplasia [5-8]. PPARs function as 
heterodimeric partners with RXR, and require high-
affinity  binding  of  PPAR  isotype-specific  ligands  to 
engage transcription. Of the three subtypes, PPARγ is 
the major species expressed in the mammary gland and 
in primary and metastatic breast cancer and breast cancer 
cell lines [5]. 
PPARγ  and  PPARδ  modulate  cell  fate  in  the 
mammary gland [6, 9, 10], suggesting that PPAR 
agonists or antagonists may have the potential to Oncotarget 2012; 3:  345-356 346 www.impactjournals.com/oncotarget
regulate differentiation and hence tumor progression. 
PPARγ agonists are potent chemopreventive agents in 
mammary carcinogenesis [11], which is consistent with 
the enhancement of mammary tumorigenesis by PPARγ 
heterozygosity [12]. In a large percentage of follicular 
thyroid cancers, PPARγ exists as the dominant-negative 
fusion protein, Pax8-PPARγ, associated with the t(2;3)
(q13;p25) translocation [13]. Pax8PPARγ potently blocks 
PPARγ function [13, 14], rather than merely serving as a 
low affinity receptor that can be activated at high ligand 
concentrations [15]. Importantly, the irreversible PPARγ 
‘suicide’ inhibitor, GW9662 [16], mimics the growth 
promoting effects of Pax8PPARγ in thyroid cells [17], 
suggesting that selective pharmacological manipulation 
of PPARγ is feasible. 
Although many studies have addressed the 
interactions between different nuclear receptor subfamilies, 
an area of relevance to breast cancer is the inhibitory effect 
of PPARγ on ERα (ER) promoter activation through its 
interaction with ER response elements [18]. Conversely, 
ER may bind to PPARγ response elements (PPREs) to 
inhibit PPAR-dependent transcription [19]. The ER and 
PPARγ pathways produce opposite effects on PI3K/AKT 
signaling, accounting in part, for the divergent responses 
produced by their cognate ligands in estrogen-dependent 
human breast cancer cells [19]. These findings suggest 
that suppression of PPARγ may upregulate ER expression 
in tumors to allow the implementation of anti-estrogen 
therapy. As a proof of principle, this was demonstrated 
by the effectiveness of the ER antagonist, fulvestrant, 
in preventing mammary tumorigenesis in MMTV-
Pax8PPARγ  mice,  in  which  tumors  normally  present 
with a more aggressive progenitor cell phenotype [10]. 
Therefore, from a chemoprevention perspective, it would 
be important to be able to mimic the MMTV-Pax8PPARγ 
transgene pharmacologically by administering a PPARγ 
antagonist  to  increase  the  percentage  of  ER+ tumors 
and render them amenable to anti-estrogen therapy. 
This approach would be dependent on whether a PPAR 
antagonist could be developed with favorable specificity 
and pharmacokinetic properties to achieve selective and 
sustained  inhibition  of  PPARγ.  Examples  of  PPARγ 
antagonists are the suicide inhibitors, GW9662 (2-chloro-
5-nitro-N-phenylbenzamide) [16], 2-bromo-5-nitro-
N-phenylbenzamide [20] and the structurally similar 
T0070907 [21], as well as the partial PPARγ agonists, 
GW0072 [22] and L-764406 [23]. Although, GW9662 
and T0070907 have also been reported to produce off-
target effects in vitro [24-26], their in vivo selectivity 
has yet to be demonstrated. In this report, we show 
that GW9662 when administered continuously in the 
diet beginning at the onset of mammary carcinogenesis 
induces ER-responsive tumors susceptible to fulvestrant 
therapy.  Furthermore,  GW9662  inhibited  a  PPARγ-
dependent metabolic gene expression signature, including 
PPARγ itself. These results are the first to demonstrate 
that GW9662 is at least in part PPARγ-selective, and can 
induce sensitivity to anti-estrogen therapy.
Figure 1: GW9662 enhances the sensitivity of 
mammary tumors to fulvestrant. (A) Survival curves 
of mice administered a control diet, a diet supplemented with 
0.1% (w/w) GW9662, 250 mg/kg fulvestrant administered s.c. 
every other week or the combination of the GW9662 diet and 
fulvestrant.    GW9662  treatment  alone  produced  a  significant 
reduction in survival vs. control mice (P=0.0382), but not vs. 
fulvestrant treatment (P=0.0759);  fulvestrant  treatment  alone 
did  not  significantly  affect  survival  (P=0.7223).    GW9662 
and  fulvestrant  treatment  produced  a  significant  increase  in 
survival vs. fulvestrant (P=0.0008) or GW9662 (P=0.0001) 
treatment  alone.    Each  group  contained  10  mice.    Statistical 
significance was determined by the log rank test.  (B) Tumor 
formation in the experimental groups indicated in (A). Neither 
GW9662 (P=0.3942)  nor  fulvestrant  (P=0.3339)  treatment 
alone  significantly  affected  tumor  number  vs.  control  mice.   
GW9662  and  fulvestrant  treatment  produced  a  significant 
reduction in tumor number vs. either fulvestrant (P=0.0001) or 
GW9662 (P=0.0004) treatment alone.  Each group contained 10 
mice.  Statistical significance was determined by the two-tailed 
Student’s t test.Oncotarget 2012; 3:  345-356 347 www.impactjournals.com/oncotarget
RESULTS
GW9662 induces sensitivity to antiestrogen 
therapy
To evaluate the chemopreventive effect of GW9662 
on mammary tumor development, carcinogenesis was 
induced in FVB mice by progestin and DMBA treatment. 
Animals were maintained on either a control diet or a 
diet supplemented with 0.1% GW9662 beginning one 
day after the last dose of DMBA, and both groups were 
administered  either  vehicle  or  250  mg/kg  fulvestrant 
by subcutaneous injection every other week (Figure 1). 
Animals maintained on GW9662 alone exhibited a modest 
reduction in survival (Figure 1A) similar to what was 
observed previously in MMTV-Pax8PPARγ transgenic 
mice [10], but not a reduction in the total number of 
tumors (Figure 1B). While no significant difference in 
survival was noted for fulvestrant-treated control mice, a 
marked increase in survival (Figure 1A) and a reduction 
in tumor number (Figure 1B) were observed in animals 
maintained on GW9662 and treated with fulvestrant. 
Consistent with these findings was an increase in ER 
expression in tumors from GW9662-treated mice in 
comparison to animals maintained on the control diet as 
determined by immunohistochemical (Figure 2A) and 
western analyses (Figure 2B). Increased ER, as well as PR 
expression, was accompanied by an increase in Esr1 and 
Pgr mRNA levels (Figure 3A). GW9662 treatment also 
resulted in a reduction of PPARγ protein (Figure 2B) and 
mRNA (Figure 3A). Histological evaluation of the tumors 
indicated that GW9662, but not fulvestrant, produced a 
significant increase in the percentage of adenocarcinomas 
(P=0.0333) (Table S1). 
Figure 2: ER expression in adenocarcinomas from control and GW9662 mice. (A) Immunohistochemical detection of 
ER expression.  Two representative tumors from control and GW9662-treated mice are shown. ER expression was increased following 
GW9662 treatment.  Magnification 200X. (B) Western analysis of ER and PPARγ expression.  Two representative tumors from control and 
GW9662-treated mice are shown.  ER expression was increased, and PPARγ expression reduced following GW9662 treatment. The bar 
graph represents quantitation of the western blot normalized to actin expression.Oncotarget 2012; 3:  345-356 348 www.impactjournals.com/oncotarget
Gene expression analysis
Gene microarray analysis of tumors from control 
and GW9662-treated animals indicated that 356 genes 
were differentially affected by GW9662 treatment (Figure 
3B). Of the 303 genes downregulated by GW9662, 24% 
were metabolic genes, and 55% of which contain PPREs 
(Table 1). In addition, there were 10 genes regulated 
by  transcription  factors  Cebpa  and  Pouf1,  which  are 
PPAR-regulated. Overall, 67% of the metabolic genes 
were directly or indirectly regulated by GW9662. Gene 
ontology of the differentially expressed genes (Table 
S1) indicated that the largest percentage were associated 
with transport, glucose and lipid metabolism, and 
developmental  processes  (Table  2).  Pathway  linkage 
analysis revealed that most of the genes whose expression 
was downregulated by GW9662 were linked directly or 
indirectly  to  PPARγ  (Figure  4),  whereas,  those  genes 
whose expression was increased by GW9662 were 
connected to Mapk3, Mapk8 and Akt signaling (Figure 
S1). Interestingly, the majority of the genes upregulated 
by GW9662 were associated with transcription, splicing, 
processing and translation of RNA (Table S2). In 
particular, RBM39, whose expression was increased 6.6-
fold by GW9662, was recently reported to be increased in 
ER-dependent mammary tumors developing in caveolin-1 
knockout mice [27].
DISCUSSION
The present study was designed to determine if 
pharmacological  inhibition  of  PPARγ  could  sensitize 
mammary tumor growth to antiestrogen therapy. This 
concept was based on our previous finding that induction 
of mammary carcinogenesis in transgenic mice expressing 
the dominant-negative Pax8PPARγ fusion protein resulted 
in increased ER expression and responsiveness to the 
ER  antagonist,  fulvestrant  [10].  MMTV-Pax8PPARγ 
transgenic mice represent a rare mouse model in which 
the mammary gland exhibits a progenitor cell phenotype 
that results in the preferential development of ER+ rather 
than ER- tumors of mixed lineage following progestin/
DMBA treatment [10, 28]. A similar mammary tumor 
phenotype developed in caveolin-1 knockout mice that 
was also associated with the induction of several stem/
progenitor  cell  markers,  including  RBM39  [27],  as 
Figure 3: (A) qRT-PCR analysis of gene expression in adenocarcinomas from control and GW9662-treated mice.  Gene 
selection was based on the data in Table 1.  (B) Heat map of changes in gene expression based on the data in Table S2.  Oncotarget 2012; 3:  345-356 349 www.impactjournals.com/oncotarget
Table 1: Metabolic genes downregulated by GW9662. Shown are genes whose signal was >300 in either group and were 
changed[3] 2.5-fold in GW9662-treated animals vs. control. The full list of changes in gene expression are presented in Table S2. Gene 
symbols in bold contain PPREs.
Raw Value
Gene 
symbol
Gene Title
Fold 
Change
WT GW9662
Ces3 carboxylesterase 3 -105.7 2733 25
Gys2 glycogen synthase 2 -74.7 558 7
Lep leptin -74.7 1231 16
Aqp7 aquaporin 7 -55.6 3523 63
Pnpla3 patatin-like phospholipase domain containing 3 -53.9 1301 24
Cox8b cytochrome c oxidase,  subunit VIIIb -51.0 1324 26
Cyp2e1 cytochrome P450 family 2,  subfamily e,  polypeptide 1 -44.3 5209 118
Pck1 phosphoenolpyruvate carboxykinase 1,  cytosolic -43.9 3071 70
Retn resistin -35.7 10637 298
Rbp4 retinol binding protein 4,  plasma -33.9 3187 94
Lao1 L-amino acid oxidase 1 -30.2 3092 103
Fabp3 fatty acid binding protein 3,  muscle and heart -27.0 886 33
Cd36 CD36 antigen -22.5 6726 306
Car4 carbonic anhydrase 4 -22.3 982 44
Fabp4 fatty acid binding protein 4,  adipocyte -21.7 7777 3543
Adipoq adiponectin, C1Q and collagen domain containing -21.6 10299 522
Adig adipogenin -20.8 1676 85
Acsl1 acyl-CoA synthetase long-chain family member 1 -18.6 3172 374
Lipe lipase,  hormone sensitive -16.2 1329 82
Hsd11b1 hydroxysteroid-11-beta dehydrogenase 1 -15.7 28.15 1.79
Pparg peroxisome proliferator activated receptor gamma -13.9 967 69
Pc pyruvate carboxylase -13.1 1588 95
Dgat2 diacylglycerol O-acyltransferase 2 -12.4 4000 521
Cel carboxyl esterase lipase -12.1 955 79
Acacb  acetyl-Coenzyme A carboxylase beta -11.5 530 46
Acaa1b acetyl-Coenzyme A acyltransferase 1B -10.6 696 66
Ephx2 epoxide hydrolase 2,  cytoplasmic -10.0 1402 140
Lpl lipoprotein lipase -9.6 6823 713
Pgam2 phosphoglycerate mutase 2 -8.9 628 70
Cox6a2 cytochrome c oxidase,  subunit VI a,  polypeptide 2 -8.1 405 50
Fasn fatty acid synthase -7.3 11558 1579
Ptger3 prostaglandin E receptor 3 (subtype EP3) -7.1 1106 157
Sorbs1 sorbin and SH3 domain containing 1 -6.5 2532 581
Pygl liver glycogen phosphorylase -6.4 1600 250
Scd1 stearoyl-Coenzyme A desaturase 1 -6.4 7943 2026
Chpt1 choline phosphotransferase 1 -5.8 1658 327
Slc1a5
solute carrier family 1 (neutral amino acid transporter),  
member 5
-5.6 2664 476
Acss2 acyl-CoA synthetase short-chain family member 2 -5.5 969 160
Mgll monoglyceride lipase -5.5 3443 632
Pnpla2 patatin-like phospholipase domain containing 2 -5.1 4552 890
Eno3 enolase 3,  beta muscle -4.9 672 136
Cyp2f2 cytochrome P450 family 2,  subfamily f,  polypeptide 2 -4.9 550 112
Lpin1 lipin 1 -4.8 1167 268
Ido1 indoleamine 2, 3-dioxygenase 1 -4.8 406 85
Sod3 superoxide dismutase 3,  extracellular -4.7 678 145
Cyp4b1 cytochrome P450 family  4,  subfamily b,  polypeptide 1 -4.6 1286 283
Igf1 insulin-like growth factor 1 -4.3 558 153
Aacs acetoacetyl-CoA synthetase -4.1 1176 320
Acox1 acyl-Coenzyme A oxidase 1,  palmitoyl -4.1 920 225
Xdh xanthine dehydrogenase -3.9 1400 362
Gpd1 glycerol-3-phosphate dehydrogenase 1 (soluble) -3.6 1710 283
Gpt2
glutamic pyruvate transaminase (alanine 
aminotransferase) 2 -3.6 1338 438
Gpt glutamic pyruvic transaminase,  soluble -3.6 577 159
Abca8a ATP-binding cassette,  sub-family A (ABC1),  member 8a -3.5 1675 478
Me1 malic enzyme 1,  NADP(+)-dependent,  cytosolic -3.4 2810 900
Aqp1 aquaporin 1 -3.4 2841 848
Retsat retinol saturase (all trans retinol 13, 14 reductase) -3.3 488 146
Slc27a1 solute carrier family 27 (fatty acid transporter),  member 1 -3.2 522 163
Lipa lysosomal acid lipase A -3.2 374 117
Fads3 fatty acid desaturase 3 -3.2 1545 485
Alox12e arachidonate lipoxygenase, epidermal -3.1 818 262
Elovl6
ELOVL family member 6,  elongation of long chain fatty 
acids (yeast)
-3.1 1088 320
Gpam glycerol-3-phosphate acyltransferase, mitochondrial -3.0 2818 947
Nr1h3 nuclear receptor subfamily 1,  group H,  member 3 (LXR) -3.0 1137 379
Acly ATP citrate lyase -2.9 993 343
Pik3r1
phosphatidylinositol 3-kinase,  regulatory subunit,  
polypeptide 1 (p85 alpha)
-2.9 558 192
Rbp7 retinol binding protein 7,  cellular -2.9 1212 418
Slc2a4
solute carrier family 2 (faciltated glucose transporter),  
member 4
-3.2 522 163
Crat carnitine acetyltransferase -2.8 537 191
Slc2a4
solute carrier family 2 (facilitated glucose transporter),  
member 4
-2.8 1021 364
Sord sorbitol dehydrogenase -2.8 700 250
Ehhadh
enoyl-Coenzyme A,  hydratase/3-hydroxyacyl Coenzyme 
A dehydrogenase
-2.7 341 126
Hk2 hexokinase 2 -2.7 1447 534
Lpgat1 lysophosphatidylglycerol acyltransferase 1 -2.7 399 150
Gbe1 glucan (1, 4-alpha-)branching enzyme -2.7 723 267
Apod apolipoprotein D -2.6 4011 1526
Gatm
glycine amidinotransferase (L-arginine:glycine 
amidinotransferase
-2.6 400 152
Ltc4s leukotriene C4 synthase -2.6 467 179
Pfkfb1 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 1 -2.6 320 124
Plin2 perilipin 2 -2.5 6773 2671
Cebpa CCAAT/enhancer binding protein (C/EBP),  alpha -2.5 1819 734
Dgat1 diacylglycerol O-acyltransferase 1 -2.5 1065 425
Ptgs1 prostaglandin-endoperoxide synthase 1 -2.5 362 145Oncotarget 2012; 3:  345-356 350 www.impactjournals.com/oncotarget
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Figure 4: GW9662 signaling pathways in tumors from control and GW9662-treated animals. Pathways are based on the 
expression of genes that were reduced ≥2.5-fold by GW9662 in Table S1. Metabolic signaling pathways associated with genes that were 
downregulated by GW9662. Oncotarget 2012; 3:  345-356 352 www.impactjournals.com/oncotarget
Table 2: Gene ontology of differentially expressed genes affected by GW9662.  Shown are enrichment data with P<0.05 by 
Fisher’s Exact test.
 
Name Total 
Entities Overlap Overlapping Entities p-value
DOWNREGULATED:
lipid metabolism 342 23
CHPT1, CD36, LEP, LPL, LIPE, APOD, 
NR1H3, SLC27A1, LIPA, ACSL1, 
HSD11B1, DGAT2, CRAT, ACLY, LPIN1, 
ACOX1, EHHADH, PNPLA2, PCK1, 
PNPLA3, MGLL, AACS, FADS3
1.92E-26
metabolism 858 21
LPGAT1, FASN, LIPE, ACACB, SLC27A1, 
EPHX2, ACSL1, GPAM, HSD11B1, ME1, 
PC, ACLY, PFKFB1, ACOX1, EHHADH, 
PNPLA2, GPD1, PNPLA3, ACSS2, 
PGAM2, AACS
3.71E-15
transport 1807 15
AQP1, CD36, APOD, SLC2A4, SLC27A1, 
FABP4, FABP3, CRAT, SORBS1, SLC1A5, 
AQP7, RBP4, CRABP1, RBP7, FADS3
6.01E-05
oxidation reduction 702 14
CYP2E1, PTGS1, SOD3, XDH, FASN, 
HSD11B1, ME1, ACOX1, EHHADH, GPD1, 
CYP4B1, SORD, RETSAT, FADS3
3.58E-09
fatty acid metabolism 110 12
CD36, PPARG, SLC27A1, LIPA, FABP4, 
ACSL1, GPAM, FABP3, CRAT, ACOX1, 
EHHADH, AACS
1.21E-16
response to drug 295 10
ADIPOQ, PPARG, LIPE, ACACB, FABP4, 
ACSL1, AQP7, SORD, ENO3, AACS 5.40E-09
response to insulin 37 10
LEP, RETN, PIK3R1, PFKFB1, PCK1, 
RBP4, PPARG, SORBS1, LPIN1, NRIH3 5.81E-10
fat cell differentiation 29 9
ADIG, CEBPA, ADIPOQ, PPARG, 
SLC2A4, FABP4, IGF1, AACS, RETN 1.21E-10
lipid biosynthesis 115 8
PTGS1, FASN, DGAT2, PC, ACLY, 
ELOVL6, ACSS2, FADS3 7.24E-10
gluconeogenesis 33 7
GPT, PC, PFKFB1, GPD1, PCK1, RBP4, 
PGAM2 2.60E-12
generation of precursor 
metabolites & energy 63 7
CEBPA, ADIPOQ, GYS2, ACOX1, AQP7, 
GBE1, COX6A2 3.17E-10
response to glucocorticoids 95 6
CEBPA, ADIPOQ, IGF1, FABP4, PIK3R1, 
PFKFB1 1.93E-07
response to nutrients 117 6
CEBPA, ADIPOQ, PPARG, ACSL1, GATM, 
AACS 6.62E-07
lipid catabolism 113 6 CEL, LPL, LIPE, LIPA, PNPLA2, PNPLA3 5.40E-07
glucose homeostasis 50 6
ADIPOQ, PPARG, SLC2A4, PCK1, RBP4, 
PYGL 3.87E-09
spermatogenesis 353 5 ADIG, ACOX1, AQP7, RBP4, PGAM2 2.38E-03
carbohydrate metabolism 296 5 SLC2A4, ME1, GPD1, PYGL, GBE1 1.10E-03
fatty acid biosynthesis 78 5 PTGS1, FASN, ACACB, ELOVL6, FADS3 1.98E-06
triglyceride biosynthesis 11 5 LPL, GPAM, DGAT1, DGAT2, PNPLA3 4.97E-11
glucose metabolism 115 5 ADIPOQ, LEP, HK2, PIK3R1, SORD 1.33E-05
inflammatory response 293 4 PPARG, LIPA, EPHX2, MGLL 7.45E-03
lung development 106 4 CEBPA, LIPA, HSD11B1, RBP4 1.78E-04
organ regeneration 49 4 CEBPA, PPARG, LPIN1, PFKFB1 8.49E-06
triglyceride catabolism 13 4 LPL, LIPE, PNPLA2, PNPLA3 3.08E-08
fatty acid beta-oxidation 32 4 ADIPOQ, FABP3, ACOX1, EHHADH 1.49E-06
glycolysis 68 4 HK2, PFKFB1, ENO3, PGAM2 3.14E-05
regulation of transcription 159 4 CEBPA, NR1H3, FABP4, PPARG 8.53E-03
response to ethanol 83 3 ADIPOQ, RBP4, AACS 1.37E-03
long-chain fatty acid transport 12 3 CD36, PPARG, FABP3 3.76E-06
aging 101 3 PTGS1, PIK3R1, ENO3 2.41E-03
fatty acid oxidation 18 3 CD36, ADIPOQ, PPARG 1.38E-05
glycogen metabolism 41 3 GYS2, PYGL, GBE1 1.72E-04
phospholipid biosynthesis 49 3 LPGAT1, CHPT1, GPAM 2.94E-04
regulation of cell proliferation 135 3 PTGS1, CEBPA, IGF1 5.44E-03
negative regulation of foam cell 
differentiation 10 3 ADIPOQ, PPARG, NR1H3 2.06E-06
UPREGULATED:
regulation of transcription 2501 9
ZBTB16, MAPK8, RHOX5, BRWD1, 
ESRRB, RBM39, TARDBP, NFIB, THRAP3 2.24E-02
RNA splicing 238 5
HNRNPA1, PABPC1, RBM39, TARDBP, 
RBMX 2.13E-05
mRNA processing 277 5
PABPN1, HNRNPA1, PABPC1, RBM39, 
TARDBP 4.40E-05
cell proliferation 324 4 PTHLH, EREG, ZBTB16, NFIB 1.13E-03
central nervous system 
development 140 3 ZBTB16, PCP4, NPTX1 1.04E-03
translational elongation 161 3 RPS25, RPS24, RPL41 1.55E-03
cell-cell signaling 275 3 CALCA, PTHLH, EREG 6.96E-03
apoptosis 550 3 ZBTB16, SLC5A8, NISCH 4.29E-02
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found in the present study. RBM39 functions primarily 
in RNA splicing and may also be a putative partner of 
the co-activator Ncoa6/PRIP [29]. Thus, one unexpected 
finding was that GW9662 upregulated a number of genes 
associated with transcription, processing, splicing and 
translation that likely contribute to the diversity of the 
proteome [30]. 
GW9662 is an irreversible PPARγ antagonist [16], 
although in vitro cell studies have also reported off-target 
effects [24-26]. However, there are no in vivo studies that 
have established whether GW9662 is PPARγ-selective. 
In one instance, GW9662 was shown to reduce high fat 
diet-induced obesity in rats when administered in the diet 
at a concentration of 0.1% [31], which was identical to 
the GW9662 diet used in our study. GW9662 was also 
shown  to  block  the  anti-inflammatory  effects  of  the 
PPARγ  agonist,  rosiglitazone,  in  endotoxin-induced 
acute lung injury after intravenous administration [32]. 
Based on gene array profiling, we found that GW9662 
elicited PPARγ specificity based on its direct and indirect 
inhibitory effects on the expression of metabolic genes 
known to be under the control of PPARs. 
An important caveat to the use of GW9662 
is its ability to induce a modest acceleration of 
tumorigenesis when administered orally at the onset 
of carcinogenesis. We also observed a similar effect in 
 
Name Total 
Entities Overlap Overlapping Entities p-value
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EHHADH, AACS
1.21E-16
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ELOVL6, ACSS2, FADS3 7.24E-10
gluconeogenesis 33 7
GPT, PC, PFKFB1, GPD1, PCK1, RBP4, 
PGAM2 2.60E-12
generation of precursor 
metabolites & energy 63 7
CEBPA, ADIPOQ, GYS2, ACOX1, AQP7, 
GBE1, COX6A2 3.17E-10
response to glucocorticoids 95 6
CEBPA, ADIPOQ, IGF1, FABP4, PIK3R1, 
PFKFB1 1.93E-07
response to nutrients 117 6
CEBPA, ADIPOQ, PPARG, ACSL1, GATM, 
AACS 6.62E-07
lipid catabolism 113 6 CEL, LPL, LIPE, LIPA, PNPLA2, PNPLA3 5.40E-07
glucose homeostasis 50 6
ADIPOQ, PPARG, SLC2A4, PCK1, RBP4, 
PYGL 3.87E-09
spermatogenesis 353 5 ADIG, ACOX1, AQP7, RBP4, PGAM2 2.38E-03
carbohydrate metabolism 296 5 SLC2A4, ME1, GPD1, PYGL, GBE1 1.10E-03
fatty acid biosynthesis 78 5 PTGS1, FASN, ACACB, ELOVL6, FADS3 1.98E-06
triglyceride biosynthesis 11 5 LPL, GPAM, DGAT1, DGAT2, PNPLA3 4.97E-11
glucose metabolism 115 5 ADIPOQ, LEP, HK2, PIK3R1, SORD 1.33E-05
inflammatory response 293 4 PPARG, LIPA, EPHX2, MGLL 7.45E-03
lung development 106 4 CEBPA, LIPA, HSD11B1, RBP4 1.78E-04
organ regeneration 49 4 CEBPA, PPARG, LPIN1, PFKFB1 8.49E-06
triglyceride catabolism 13 4 LPL, LIPE, PNPLA2, PNPLA3 3.08E-08
fatty acid beta-oxidation 32 4 ADIPOQ, FABP3, ACOX1, EHHADH 1.49E-06
glycolysis 68 4 HK2, PFKFB1, ENO3, PGAM2 3.14E-05
regulation of transcription 159 4 CEBPA, NR1H3, FABP4, PPARG 8.53E-03
response to ethanol 83 3 ADIPOQ, RBP4, AACS 1.37E-03
long-chain fatty acid transport 12 3 CD36, PPARG, FABP3 3.76E-06
aging 101 3 PTGS1, PIK3R1, ENO3 2.41E-03
fatty acid oxidation 18 3 CD36, ADIPOQ, PPARG 1.38E-05
glycogen metabolism 41 3 GYS2, PYGL, GBE1 1.72E-04
phospholipid biosynthesis 49 3 LPGAT1, CHPT1, GPAM 2.94E-04
regulation of cell proliferation 135 3 PTGS1, CEBPA, IGF1 5.44E-03
negative regulation of foam cell 
differentiation 10 3 ADIPOQ, PPARG, NR1H3 2.06E-06
UPREGULATED:
regulation of transcription 2501 9
ZBTB16, MAPK8, RHOX5, BRWD1, 
ESRRB, RBM39, TARDBP, NFIB, THRAP3 2.24E-02
RNA splicing 238 5
HNRNPA1, PABPC1, RBM39, TARDBP, 
RBMX 2.13E-05
mRNA processing 277 5
PABPN1, HNRNPA1, PABPC1, RBM39, 
TARDBP 4.40E-05
cell proliferation 324 4 PTHLH, EREG, ZBTB16, NFIB 1.13E-03
central nervous system 
development 140 3 ZBTB16, PCP4, NPTX1 1.04E-03
translational elongation 161 3 RPS25, RPS24, RPL41 1.55E-03
cell-cell signaling 275 3 CALCA, PTHLH, EREG 6.96E-03
apoptosis 550 3 ZBTB16, SLC5A8, NISCH 4.29E-02
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MMTV-Pax8PPARγ  mice  following  progestin/DMBA 
mammary carcinogenesis [10]. While this has not been 
reported previously, the ability of GW9662 to inhibit 
cell growth in vitro similarly to PPARγ agonists [24, 33, 
34]  suggests  the  presence  of  “off-target”  effects. The 
increase in tumorigenesis observed with GW9662 and the 
dominant-negative Pax8PPARγ transgene suggests that 
partial antagonists rather than full antagonists or drugs 
with greater specificity may be a useful approach for 
further studies. Clearly, additional pharmacokinetic and 
pharmacodynamic studies in vivo are needed to establish 
the bioavailability and metabolic effects of GW9662. 
Overall, the positive aspect of inhibiting PPARγ was its 
ability to sensitize tumors to the ER antagonist fulvestrant, 
suggesting the potential for such an approach for hormone-
insensitive malignancies. 
MATERIALS AND METHODS
Animal model
FVB  wild-type  (WT)  mice  were  obtained  from 
Taconic Farms, Germantown, N.Y. All animal studies were 
conducted under protocols approved by the Georgetown 
University Animal Care and Use Committee.
Mammary carcinogenesis
Five  week-old  WT  mice  were  treated  with 
medroxyprogesterone acetate and DMBA as previously 
described [9, 28]. Briefly, mice were injected s.c. with 
15 mg medroxyprogesterone acetate suspension (Depo-
Provera?), and after seven days were administered four 
weekly doses of 1 mg DMBA/0.1 ml cottonseed oil by 
gavage. One day after the last dose of DMBA, mice were 
divided into four groups of 10 mice each: 1) one group was 
maintained on standard Purina Rodent Chow 5001, 2) one 
group was maintained on chow supplemented with 0.1% 
(w/w) GW9962, 2) one group was maintained on chow 
supplemented with GW9662 and injected s.c. every other 
week with 250 mg/kg fulvestrant (Faslodex®) and 4) one 
group was injected with 250 mg/kg fulvestrant every other 
week. GW9662 was provided by the Chemoprevention 
Branch, NCI. The histopathology of the resulting tumors 
is presented in Table S1.
Antibodies
The source of antibodies, their dilution and use 
were the following: rabbit anti-ERα (sc-542, Santa Cruz 
Biotechnology, 1:200 for IHC, 1:1,000 for western); rabbit 
anti-PgR (sc-538, Santa Cruz Biotechnology, 1:200 for 
IHC, 1:1,000 for western). 
Immunohistochemistry
IHC analysis was carried out as previously described 
[9, 10, 28]. 
Western Blotting
Western blotting was carried out as previously 
described  [10].  Briefly,  tissue  was  frozen  in  liquid 
nitrogen and pulverized in a mortar and pestle, and mixed 
with lysis buffer containing: 0.1% SDS, 0.5% NP-40, 
phenylmethylsulfonyl fluoride, 1 mM sodium vanadate, 50 
mM sodium fluoride, 10 mM β-glycerophosphate, 5 mM 
sodium pyrophosphate, and protease inhibitor cocktail 
(Roche Diagnostics). Following incubation on ice for 30 
min, lysates were cleared by centrifugation for 15 min at 
13,000 x g at 4oC. Protein concentrations were determined 
by the Coomassie Plus Protein Assay (Pierce), and 50 μg 
of lysate was separated in a 4-12% NuPAGE Bis-Tris gel 
(Invitrogen). After wet transfer, membranes were blocked 
for 1 hr at room temperature in TBS (pH 7.4) containing 
5%  non-fat  dry  milk  and  0.1%  Tween  20.  Primary 
antibody was incubated overnight at 4°C, and secondary 
antibody was incubated for 1 hr at room temperature. 
Proteins were visualized with either SuperSignal West 
Pico or SuperSignal West Dura (Pierce). 
Gene Microarray Analysis 
Total RNA was extracted using an RNeasy Mini 
Kit (Qiagen) following the manufacturer’s protocol as 
previously described [10, 35]. cRNA was synthesized 
using the Affymetrix (Santa Clara, CA) protocol with 
minor  modifications  as  described  [28].  Biotin-labeled 
cRNA was fragmented for 35 min at 94°C and hybridized 
overnight to an Affymetrix mouse 430A 2.0 GeneChip® 
representing approximately 22,000 annotated mouse genes 
by  the  Genomics  and  Epigenomics  Shared  Resource, 
Lombardi Comprehensive Cancer Center, Georgetown 
University. Hybridization signals were detected with an 
Agilent Gene Array scanner, and grid alignment and raw 
data generation performed with Affymetrix GeneChip® 
Operating software 1.1. Changes in gene expression with 
a signal ≥300 (log2 ≥8.1) and ≥3-fold change [9, 35, 36] 
were  clustered  hierarchically  with  CIMiner  software 
(National Cancer Institute, NIH). Array data are presented 
in Table S2, and complete data files were deposited in the 
GEO database under accession no. GSE33762.
Quantitative Real-Time Polymerase Chain Reaction 
(qRT-PCR) 
Total RNA was extracted using the RNAeasy 
Mini  Kit  (Qiagen,  Valencia,  CA)  according  to  the 
manufacturer’s protocol as previously described [10, 
35]. One µg of RNA was reverse transcribed in a total 
volume of 20 µl  using  the  Cloned AMV  First-Strand 
cDNA Synthesis kit (Invitrogen). PCR was performed 
in  triplicate  in  an  ABI  7900  instrument  (Applied 
Biosystems, Foster City, CA) using SYBRGreen detection 
(Applied Biosystems, Foster City, CA) according to the 
manufacturer’s protocol. qRT-PCR primers were designed 
using the primer design tool at http://www.idtdna.com/
Scitools/Applications/RealTimePCR/. Efficiencies of all Oncotarget 2012; 3:  345-356 355 www.impactjournals.com/oncotarget
primer sets (Table S1) were validated using a standard 
curve of five serial cDNA dilutions in water in duplicate. 
Primers were acceptable if the deviation from the slope 
of the standard curve was <0.3, and if the melting curve 
showed only one product. The expression of each target 
gene was normalized to the expression of GAPDH, and 
the  relative  quantification  method  was  applied  using 
SDS2.3 software (Applied Biosystems, Foster City, CA). 
Primers are listed in Table S3.
Statistical Analysis
Survival curves were analyzed by Pearson’s log rank 
test and cumulative tumor formation by Student’s two-
tailed t test at a significance level of P≤0.05.
ACKNOWLEDGEMENTS
This study was supported by contract 1NO1 
CN43302-WA19  from  the  National  Cancer  Institute, 
NIH, and award P30CA051008 from the National Cancer 
Institute, NIH to the Lombardi Comprehensive Cancer 
Center (LCCC). This investigation was conducted using 
the Animal Research, Flow Cytometry, Genomics and 
Epigenomics,  and  Microscopy  and  Imaging  Shared 
Resources  of  the  LCCC,  and  by  an  animal  facilities 
construction grant from the NIH.
REFERENCES
1.  Berger JP, Akiyama TE and Meinke PT. PPARs: therapeutic 
targets for metabolic disease. Trends Pharmacol Sci. 2005; 
26(5):244-251.
2.  Barish GD, Narkar VA and Evans RM. PPAR delta: a 
dagger in the heart of the metabolic syndrome. The Journal 
of clinical investigation. 2006; 116(3):590-597.
3.  Evans RM, Barish GD and Wang YX. PPARs and the 
complex journey to obesity. Nat Med. 2004; 10(4):355-361.
4.  Lehrke M and Lazar MA. The many faces of PPARgamma. 
Cell. 2005; 123(6):993-999.
5.  Michalik  L,  Desvergne  B  and  Wahli  W.  Peroxisome-
proliferator-activated receptors and cancers: complex 
stories. Nat Rev Cancer. 2004; 4(1):61-70.
6.  Glazer RI, Yuan H, Xie Z and Yin Y. PPARgamma and 
PPARdelta  as  Modulators  of  Neoplasia  and  Cell  Fate. 
PPAR Res. 2008; 2008:247379.
7.  Kopelovich  L,  Fay  JR,  Glazer  RI  and  Crowell  JA. 
Peroxisome proliferator-activated receptor modulators as 
potential chemopreventive agents. Mol Cancer Ther. 2002; 
1(5):357-363.
8.  Koeffler HP. Peroxisome proliferator-activated receptor 
gamma and cancers. Clin Cancer Res. 2003; 9(1):1-9.
9.  Yin Y, Russell RG, Dettin LE, Bai R, Wei ZL, Kozikowski 
AP, Kopelovich L and Glazer RI. Peroxisome proliferator-
activated receptor delta and gamma agonists differentially 
alter tumor differentiation and progression during mammary 
carcinogenesis. Cancer Res. 2005; 65(9):3950-3957.
10.  Yin Y, Yuan H, Zeng X, Kopelovich L and Glazer RI. 
Inhibition of peroxisome proliferator-activated receptor 
gamma increases estrogen receptor-dependent tumor 
specification. Cancer Res. 2009; 69(2):687-694.
11.  Suh  N,  Wang  Y,  Williams  CR,  Risingsong  R,  Gilmer 
T,  Willson  TM  and  Sporn  MB.  A  new  ligand  for  the 
peroxisome proliferator-activated receptor-gamma (PPAR-
gamma), GW7845, inhibits rat mammary carcinogenesis. 
Cancer Res. 1999; 59(22):5671-5673.
12.  Nicol CJ, Yoon M, Ward JM, Yamashita M, Fukamachi 
K, Peters JM and Gonzalez FJ. PPARgamma influences 
susceptibility to DMBA-induced mammary, ovarian and 
skin  carcinogenesis.  Carcinogenesis.  2004;  25(9):1747-
1755.
13.  Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, 
Spiegelman BM and Fletcher JA. PAX8-PPARgamma1 
fusion oncogene in human thyroid carcinoma Science. 
2000; 289(5483):1357-1360.
14.  Yin  Y,  Yuan  H,  Wang  C,  Pattabiraman  N,  Rao  M, 
Pestell RG and Glazer RI. 3-Phosphoinositide-Dependent 
Protein Kinase-1 Activates the Peroxisome Proliferator-
Activated Receptor-{gamma} and Promotes Adipocyte 
Differentiation. Mol Endocrinol. 2006; 20:268-278.
15.  Agostini  M,  Schoenmakers  E,  Mitchell  C,  Szatmari  I, 
Savage D, Smith A, Rajanayagam O, Semple R, Luan J, 
Bath L, Zalin A, Labib M, Kumar S, Simpson H, Blom D, 
Marais D, et al. Non-DNA binding, dominant-negative, 
human PPARgamma mutations cause lipodystrophic insulin 
resistance. Cell Metab. 2006; 4(4):303-311.
16.  Leesnitzer LM, Parks DJ, Bledsoe RK, Cobb JE, Collins JL, 
Consler TG, Davis RG, Hull-Ryde EA, Lenhard JM, Patel 
L, Plunket KD, Shenk JL, Stimmel JB, Therapontos C, 
Willson TM and Blanchard SG. Functional consequences 
of  cysteine  modification  in  the  ligand  binding  sites  of 
peroxisome proliferator activated receptors by GW9662. 
Biochemistry. 2002; 41(21):6640-6650.
17.  Gregory Powell J, Wang X, Allard BL, Sahin M, Wang 
XL,  Hay  ID,  Hiddinga  HJ,  Deshpande  SS,  Kroll  TG, 
Grebe  SK,  Eberhardt  NL  and  McIver  B.  The  PAX8/
PPARgamma fusion oncoprotein transforms immortalized 
human thyrocytes through a mechanism probably involving 
wild-type  PPARgamma  inhibition.  Oncogene.  2004; 
23(20):3634-3641.
18.  Keller H, Givel F, Perroud M and Wahli W. Signaling cross-
talk between peroxisome proliferator-activated receptor/
retinoid X receptor and estrogen receptor through estrogen 
response elements. Mol Endocrinol. 1995; 9(7):794-804.
19.  Bonofiglio D, Gabriele S, Aquila S, Catalano S, Gentile 
M, Middea E, Giordano F and Ando S. Estrogen receptor 
alpha binds to peroxisome proliferator-activated receptor 
response element and negatively interferes with peroxisome 
proliferator-activated receptor gamma signaling in breast 
cancer cells. Clin Cancer Res. 2005; 11(17):6139-6147.Oncotarget 2012; 3:  345-356 356 www.impactjournals.com/oncotarget
20.  Lee  H,  Finck  BN,  Jones  LA,  Welch  MJ  and  Mach 
RH.  Synthesis  and  evaluation  of  a  bromine-76-
labeled PPARgamma antagonist 2-bromo-5-nitro-N-
phenylbenzamide. Nucl Med Biol. 2006; 33(7):847-854.
21.  Lee G, Elwood F, McNally J, Weiszmann J, Lindstrom M, 
Amaral K, Nakamura M, Miao S, Cao P, Learned RM, Chen 
JL and Li Y. T0070907, a selective ligand for peroxisome 
proliferator-activated receptor gamma, functions as an 
antagonist of biochemical and cellular activities. J Biol 
Chem. 2002; 277(22):19649-19657.
22.  Oberfield  JL,  Collins  JL,  Holmes  CP,  Goreham  DM, 
Cooper JP, Cobb JE, Lenhard JM, Hull-Ryde EA, Mohr 
CP, Blanchard SG, Parks DJ, Moore LB, Lehmann JM, 
Plunket K, Miller AB, Milburn MV, et al. A peroxisome 
proliferator-activated receptor gamma ligand inhibits 
adipocyte differentiation. Proc Natl Acad Sci U S A. 1999; 
96(11):6102-6106.
23.  Elbrecht A, Chen Y, Adams A, Berger J, Griffin P, Klatt 
T, Zhang B, Menke J, Zhou G, Smith RG and Moller 
DE. L-764406 is a partial agonist of human peroxisome 
proliferator-activated receptor gamma. The role of Cys313 
in ligand binding. J Biol Chem. 1999; 274(12):7913-7922.
24.  Seargent JM, Yates EA and Gill JH. GW9662, a potent 
antagonist of PPARgamma, inhibits growth of breast 
tumour cells and promotes the anticancer effects of the 
PPARgamma agonist rosiglitazone, independently of 
PPARgamma activation. Br J Pharmacol. 2004; 143(8):933-
937.
25.  Lecomte  J,  Flament  S,  Salamone  S,  Boisbrun  M, 
Mazerbourg  S,  Chapleur  Y  and  Grillier-Vuissoz  I. 
Disruption of ERalpha signalling pathway by PPARgamma 
agonists: evidences of PPARgamma-independent events 
in two hormone-dependent breast cancer cell lines. Breast 
Cancer Res Treat. 2008.
26.  Schaefer KL, Takahashi H, Morales VM, Harris G, Barton 
S, Osawa E, Nakajima A and Saubermann LJ. PPARgamma 
inhibitors reduce tubulin protein levels by a PPARgamma, 
PPARdelta and proteasome-independent mechanism, 
resulting in cell cycle arrest, apoptosis and reduced 
metastasis of colorectal carcinoma cells. Int J Cancer. 2007; 
120(3):702-713.
27.  Cavallo  F,  Astolfi  A,  Iezzi  M,  Cordero  F,  Lollini  PL, 
Forni  G  and  Calogero  R.  An  integrated  approach  of 
immunogenomics and bioinformatics to identify new 
Tumor Associated Antigens (TAA) for mammary cancer 
immunological prevention. BMC Bioinformatics. 2005; 6 
Suppl 4:S7.
28.  Yin Y, Bai R, Russell RG, Beildeck ME, Xie Z, Kopelovich 
L and Glazer RI. Characterization of medroxyprogesterone 
and DMBA-induced multilineage mammary tumors by gene 
expression profiling. Mol Carcinog. 2005; 44(1):42-50.
29.  Astolfi A, Landuzzi L, Nicoletti G, De Giovanni C, Croci 
S, Palladini A, Ferrini S, Iezzi M, Musiani P, Cavallo F, 
Forni G, Nanni P and Lollini PL. Gene expression analysis 
of immune-mediated arrest of tumorigenesis in a transgenic 
mouse model of HER-2/neu-positive basal-like mammary 
carcinoma. Am J Pathol. 2005; 166(4):1205-1216.
30.  David CJ and Manley JL. Alternative pre-mRNA splicing 
regulation in cancer: pathways and programs unhinged. 
Genes Dev. 2010; 24(21):2343-2364.
31.  Nakano R, Kurosaki E, Yoshida S, Yokono M, Shimaya A, 
Maruyama T and Shibasaki M. Antagonism of peroxisome 
proliferator-activated receptor gamma prevents high-fat 
diet-induced obesity in vivo. Biochem Pharmacol. 2006; 
72(1):42-52.
32.  Liu D, Zeng BX, Zhang SH, Wang YL, Zeng L, Geng ZL 
and Zhang SF. Rosiglitazone, a peroxisome proliferator-
activated receptor-gamma agonist, reduces acute lung injury 
in endotoxemic rats. Crit Care Med. 2005; 33(10):2309-
2316.
33.  Burton JD, Castillo ME, Goldenberg DM and Blumenthal 
RD.  Peroxisome  proliferator-activated  receptor-gamma 
antagonists exhibit potent antiproliferative effects versus 
many hematopoietic and epithelial cancer cell lines. 
Anticancer Drugs. 2007; 18(5):525-534.
34.  Kim KR, Choi HN, Lee HJ, Baek HA, Park HS, Jang KY, 
Chung  MJ  and  Moon  WS.  A  peroxisome  proliferator-
activated receptor gamma antagonist induces vimentin 
cleavage and inhibits invasion in high-grade hepatocellular 
carcinoma. Oncol Rep. 2007; 18(4):825-832.
35.  Pollock  C,  Yin  Y,  Yuan  H,  Zeng  X,  King  S,  Li  X, 
Kopelovich L, Albanese C and Glazer RI. PPARδ activation 
acts  cooperatively  with  3-phosphoinositide-dependent 
protein  kinase-1  to  enhance  mammary  tumorigenesis. 
PLoSONE. 2011; 6(1):e16215.
36.  Yuan H, Upadhyay G, Yin Y, Kopelovich L and Glazer 
RI.  Stem  Cell  Antigen-1  Deficiency  Enhances  the 
Chemopreventive  Effect  of  Peroxisome  Proliferator-
Activated Receptor{gamma} Activation. Cancer Prev Res 
(Phila). 2011; 4(12):1-10.